Medicinova (MNOV) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Medicinova (MNOV) has outperformed NeOnc Technologies (NTHI) over the past year, gaining 23.6% versus a loss of 76.8%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $74.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | NTHI |
|---|---|---|
| Share price | $1.52 | $2.78 |
| Market cap | $74.82M | $80.08M |
| 1-day change | -1.30% | +9.88% |
| YTD return | +16.03% | -66.38% |
| 1-year return | +23.58% | -76.79% |
| 5-year return | -60.21% | — |
| EPS (TTM) | $-0.21 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $12.09 |
| 52-week low | $1.17 | $2.50 |
| Distance from 52-week high | -61.03% | -77.01% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +442.76% | +511.51% |
| Average volume | 323.39K | 197.21K |
| Shares outstanding | 49.22M | 28.81M |
| Employees | 6 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed NTHI by 100.4 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
MNOV vs NTHI FAQ
Which is bigger, Medicinova or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.08M compared with $74.82M for Medicinova (MNOV).
Which stock has performed better over the past year, MNOV or NTHI?
MNOV returned +23.58% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.